ArticleBioengineered2022
Perillaldehyde inhibits bone metastasis and receptor activator of nuclear factor-κB ligand (RANKL) signaling-induced osteoclastogenesis in prostate cancer cell lines.
Article in Bioengineered, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 35 citations in OpenAlex.
- Pharmacological effects, classification, genetic and molecular studies of different chemotypes essential oil ofJournal of pharmaceutical analysis · 2026Review
- Bioactive compounds from Perilla frutescens modulate multiple cell death pathways and signaling networks in cancer therapy.Frontiers in pharmacology · 2026Review
- Preparation and properties of chitosan/zein-perilla essential oil composite film: its structure, physicochemical characterization, and antioxidant properties.Frontiers in nutrition · 2026Article
- Unlocking the Potential of Perillaldehyde: A Novel Mechanism for Chronic Myeloid Leukemia by Targeting HSP70.Molecules (Basel, Switzerland) · 2025Article
- Perillaldehyde Improves Parkinson-Like Deficits by Targeting G3BP Mediated Stress Granule Assembly in Preclinical Models.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Inhibition of Colorectal Cancer by Perillaldehyde Through Targeting SRD5A1 to Induce Autophagy via the PI3K/AKT Pathway.Drug design, development and therapy · 2025Article
- Perillaldehyde synergizes with ferroptosis inducers to promote ferroptotic cell death in gastric cancer.Frontiers in cell and developmental biology · 2025Article
- An In Vitro Evaluation and Network Pharmacology Analysis of Prospective Anti-Prostate Cancer Activity fromPlants (Basel, Switzerland) · 2023Article
- The Role and Mechanism ofMolecules (Basel, Switzerland) · 2023Review
- Comparing the effects of essential oils and methanolic extracts on the inhibition of Aspergillus flavus and Aspergillus parasiticus growth and production of aflatoxins.Mycotoxin research · 2023Article
- Review
- An Ethanol Extract ofMolecules (Basel, Switzerland) · 2023Article
- Let's Go 3D! New Generation of Models for Evaluating Drug Response and Resistance in Prostate Cancer.International journal of molecular sciences · 2023Review
- In Vitro Investigation of the Anticancer Properties of Ammodaucus LeucotrichusPharmaceuticals (Basel, Switzerland) · 2022Article
- Effects of urolithin A on osteoclast differentiation induced by receptor activator of nuclear factor-κB ligand via bone morphogenic protein 2.Bioengineered · 2022Article
- Formation of pre-metastatic bone niche in prostate cancer and regulation of traditional chinese medicine.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Perillaldehyde (PAH), one of the active ingredients of the traditional Chinese medicine (TCM) plant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.